Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications

• Published in: Cytokine (Philadelphia, Pa.) Vol. 76; no. 2; pp. 156 - 162
• Main Authors: Adly, Amira A.M., Ismail, Eman A., Tawfik, Lamis M., Ebeid, Fatma S.E., Hassan, Asmaa A.S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2015
• Subjects: Adolescent; Biomarkers - blood; Body Mass Index; C-Reactive Protein - analysis; Child; Cross-Sectional Studies; Cytokines - blood; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - physiopathology; Diabetic Angiopathies - blood; EMAP II; Female; Glycated Hemoglobin A - urine; Growth Inhibitors - blood; Humans; Inflammation; Male; Micro-vascular complications; Microvessels; Neoplasm Proteins - blood; RNA-Binding Proteins - blood; ROC Curve; Type 1 diabetes; Type 1 diabetes; Micro-vascular complications; EMAP II
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2015.06.006

•We determined EMAP II in young patients with type 1 diabetes.•EMAP II was elevated in patients with and without micro-vascular complications.•EMAP II was increased in patients with microalbuminuria than normoalbuminuric group.•EMAP II levels are related to inflammation, glycemic control, albuminuria level. Objectives: Endothelial monocyte-activating polypeptide II (EMAP II) is a multifunctional polypeptide with proinflammatory and antiangiogenic activity. Hyperglycemia and dyslipidemia appears to be significant factors contributing to increased EMAP-II levels. We determined serum EMAP II in children and adolescents with type 1 diabetes as a potential marker for micro-vascular complications and assessed its relation to inflammation and glycemic control. Methods: Eighty children and adolescents with type 1 diabetes were divided into 2 groups according to the presence of micro-vascular complications and compared with 40 healthy controls. High-sensitivity C-reactive protein (hs-CRP), hemoglobin A1c (HbA1c) and EMAP II levels were assessed. Results: Serum EMAP II levels were significantly increased in patients with micro-vascular complications (1539±321.5pg/mL) and those without complications (843.6±212.6pg/mL) compared with healthy controls (153.3±28.3pg/mL; p<0.001). EMAP II was increased in patients with microalbuminuria than normoalbuminuric group (p<0.001). Significant positive correlations were found between EMAP II levels and body mass index, fasting blood glucose, HbA1c, serum creatinine, triglycerides, total cholesterol, urinary albumin creatinine ratio (UACR) and hs-CRP (p<0.05). A cutoff value of EMAP II at 1075pg/mL could differentiate diabetic patients with and without micro-vascular complications with a sensitivity of 93% and specificity of 82%. Conclusions: We suggest that EMAP II is elevated in type 1 diabetic patients, particularly those with micro-vascular complications. EMAP II levels are related to inflammation, glycemic control, albuminuria level of patients and the risk of micro-vascular complications.